Omnicell (NASDAQ:OMCL) Upgraded at StockNews.com

Omnicell (NASDAQ:OMCLGet Rating) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

A number of other analysts also recently issued reports on the stock. KeyCorp lowered their price target on shares of Omnicell from $130.00 to $75.00 and set an “overweight” rating on the stock in a report on Thursday, November 3rd. SVB Leerink decreased their price objective on shares of Omnicell from $117.00 to $54.00 and set a “market perform” rating on the stock in a report on Thursday, November 3rd. JPMorgan Chase & Co. decreased their price objective on shares of Omnicell from $140.00 to $57.00 and set a “neutral” rating on the stock in a report on Friday, November 18th. Craig Hallum decreased their price objective on shares of Omnicell from $185.00 to $75.00 in a report on Thursday, November 3rd. Finally, Piper Sandler decreased their price objective on shares of Omnicell to $55.00 in a report on Wednesday, December 14th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Omnicell currently has a consensus rating of “Moderate Buy” and an average target price of $82.11.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $55.48 on Friday. The company has a market cap of $2.46 billion, a PE ratio of 54.39, a price-to-earnings-growth ratio of 4.86 and a beta of 0.89. Omnicell has a twelve month low of $46.11 and a twelve month high of $168.18. The company’s 50 day moving average is $50.42 and its 200 day moving average is $81.76. The company has a current ratio of 2.25, a quick ratio of 1.86 and a debt-to-equity ratio of 0.50.

Omnicell (NASDAQ:OMCLGet Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.04. Omnicell had a net margin of 3.67% and a return on equity of 9.74%. The firm had revenue of $348.06 million for the quarter, compared to the consensus estimate of $362.72 million. On average, sell-side analysts forecast that Omnicell will post 1.62 EPS for the current year.

Insider Activity

In other news, EVP Scott Peter Seidelmann sold 1,793 shares of the stock in a transaction dated Monday, November 28th. The shares were sold at an average price of $51.46, for a total value of $92,267.78. Following the completion of the sale, the executive vice president now directly owns 38,996 shares in the company, valued at $2,006,734.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, EVP Scott Peter Seidelmann sold 1,793 shares of the stock in a transaction dated Monday, November 28th. The shares were sold at an average price of $51.46, for a total value of $92,267.78. Following the completion of the sale, the executive vice president now directly owns 38,996 shares in the company, valued at $2,006,734.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Randall A. Lipps sold 2,500 shares of the stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $50.78, for a total transaction of $126,950.00. Following the completion of the sale, the chief executive officer now owns 88,348 shares of the company’s stock, valued at $4,486,311.44. The disclosure for this sale can be found here. Insiders sold 9,674 shares of company stock worth $476,839 over the last three months. Insiders own 2.76% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Several hedge funds and other institutional investors have recently bought and sold shares of OMCL. MetLife Investment Management LLC increased its position in Omnicell by 55.4% during the first quarter. MetLife Investment Management LLC now owns 23,169 shares of the company’s stock worth $3,000,000 after purchasing an additional 8,257 shares during the last quarter. Rhumbline Advisers increased its position in Omnicell by 6.4% during the first quarter. Rhumbline Advisers now owns 111,098 shares of the company’s stock worth $14,386,000 after purchasing an additional 6,657 shares during the last quarter. Great West Life Assurance Co. Can increased its position in Omnicell by 0.4% during the first quarter. Great West Life Assurance Co. Can now owns 37,956 shares of the company’s stock worth $5,036,000 after purchasing an additional 144 shares during the last quarter. Raymond James Trust N.A. increased its position in shares of Omnicell by 10.9% during the first quarter. Raymond James Trust N.A. now owns 3,881 shares of the company’s stock valued at $503,000 after acquiring an additional 382 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Omnicell by 0.6% during the first quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock valued at $109,901,000 after acquiring an additional 4,839 shares during the last quarter.

About Omnicell

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Featured Articles

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.